BUSINESS WIRE
SANTA ANA, Calif.--(BUSINESS WIRE)--June 16, 2008--Advanced
Medical Optics, Inc. (AMO) (NYSE: EYE), a global leader in ophthalmic
surgical devices and eye care products, has announced a collaboration
with the Institute for Eye Research (IER) to develop contact lens
disinfectant and cleaning solutions and related products.
IER is a non-profit research organization that conducts
collaborative and contract research with and for industry in the area
of vision correction, eye care, the anterior eye, contact lenses,
contact lens care and patient management, to avoid contact lens
complications. The organization is a world leader in the in vitro and
clinical evaluation of silicone hydrogel lenses and their interaction
with contact lens care products using their proprietary modeling
systems and databases.
"IER's world-class scientists and clinicians have had a major
impact on the development of contact lenses and lens care
technologies," said AMO Executive Vice President, Research and
Development Leonard Borrmann. "We look forward to working closely with
the IER on the development of next-generation contact lens solutions."
"Through our collaboration with AMO, we will work to develop, test
and deliver, through product innovation and education, the best in
contact lens care products," said IER CEO Brien Holden, PhD. "Our goal
is to develop new, safer, better and more convenient initiatives in
the field of contact lens cleaning and disinfection systems, including
the containers for storage, cleaning and disinfection."
IER is headquartered in Sydney, Australia.
About Advanced Medical Optics (AMO)
AMO is focused on providing the full range of advanced refractive
technologies and support to help eye care professionals deliver
optimal vision and lifestyle experiences to patients of all ages.
Products in the cataract line include monofocal intraocular lenses
(IOLs), phacoemulsification systems, viscoelastics, and related
products used in ocular surgery. AMO owns or has the rights to such
product brands as Tecnis(R), Clariflex(R) and Sensar(R) IOLs;
Sovereign(R), Sovereign(R) Compact and WhiteStar Signature(TM)
phacoemulsification systems with WhiteStar(R) technology; Healon(R)
viscoelastics and the Baerveldt(R) glaucoma shunt. Products in the
refractive line include wavefront diagnostic devices, femtosecond
lasers and associated patient interface devices; excimer laser vision
correction systems and treatment cards, and refractive implants. AMO
brands in the refractive business include iDesign(TM), iFS(TM), Star
S4 IR(R), WaveScan Wavefront(R), Advanced CustomVue(TM), IntraLase(R),
IntraLasik(R) and ReZoom(R), Tecnis(R) Multifocal and Verisyse(R)
IOLs. Products in the eye care line include disinfecting solutions,
enzymatic cleaners, lens rewetting drops and artificial tears. Among
the eye care product brands the company possesses are COMPLETE(R),
COMPLETE(R) Blink-N-Clean(R), Consept(R)F, Consept(R) 1 Step,
Oxysept(R) 1 Step, UltraCare(R), Ultrazyme(R), Total Care(TM) and
blink(TM) branded products. AMO is based in Santa Ana, California, and
employs approximately 4,000 worldwide. The company has operations in
24 countries and markets products in approximately 60 countries. For
more information, visit the company's Website at www.amo-inc.com.
About The Institute for Eye Research (IER)
The Institute for Eye Research Limited is dedicated to the
proposition of "Vision excellence for all people." For more than 20
years, the Institute has collaborated with the world's leading
researchers to bring innovation in vision. An Australian
not-for-profit organization, IER has grown to be a major participant
and supporter of research worldwide and is committed to the
advancement of vision science and the provision of sustainable eye
care services and education in developing communities. For more
information please go to www.ier.org.au
Forward-Looking Statements
This press release contains forward-looking statements about AMO,
including statements by Dr. Borrmann and Professor Holden and
statements relating to development of next-generation contact lens
care products. All forward-looking statements in this press release
represent AMO's judgment only as of the date of this press release.
Actual results may differ from current expectations based on a number
of factors, including, but not limited to, unexpected delays or costs
associated with the research and development of testing standards and
new formulas for contact lens care products, continued acceptance of
our current products, and unexpected changes in competitive,
regulatory and market conditions. Therefore, the reader is cautioned
not to rely on these forward-looking statements. AMO disclaims any
intent or obligation to update these forward-looking statements.
Additional information concerning these and other risk factors may be
found in previous press releases issued by AMO and AMO's public
periodic filings with the Securities and Exchange Commission,
including the discussion under the heading "Risk Factors" in AMO's
2007 Form 10-K filed in March 2008. Copies of press releases and
additional information about AMO are available at www.amo-inc.com.